Health Care • Medical/Dental Instruments
$242.48 ▲ +61.05
(+33.65%)
MKT CAP: $14.35B • VOL: 5.42M
52W L $81 52W H $249
GKOS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $507.4M | $383.5M | $314.7M |
| YoY Revenue Growth % | +32.3% | +21.9% | — |
| Gross Profit | $282.8M | $289.5M | $138.5M |
| Gross Margin % | 55.7% | 75.5% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$199.6M | -$122.4M | -$128.7M |
| Operating Margin % | -39.3% | -31.9% | -40.9% |
| Net Income (GAAP) | -$187.7M | -$146.4M | -$134.7M |
| EBITDA (Normalized) | -$193.5M | -$117.3M | -$117.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.8M | -$61.3M | -$57.8M |
| Capital Expenditures (CapEx) | $7.7M | $6.3M | $14.2M |
| Free Cash Flow (FCF) | -$22.5M | -$67.6M | -$71.9M |
| FCF Margin % | -4.4% | -17.6% | -22.9% |
| Return on Invested Capital (ROIC %) | -23.5% | -14.0% | -2.1% |
| Cash & Short-Term Equivalents | $90.8M | $169.6M | $868.4M |
| Total Debt (Short + Long Term) | $106.8M | $93.5M | $1.85B |
| Total Stockholders' Equity | $656.2M | $766.9M | $3.79B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GKOS.